Egetis Therapeutics Q2’23: Closing in - Redeye

Redeye updates its view of Egetis the Q2 report and recent events in the company. We still see significant upside in Egetis and see good opportunities for a comeback in the share the upcoming quarters as the company should advance into a commercial company in 2024

Länk till analysen i sin helhet: https://www.redeye.se/research/936807/egetis-therapeutics-q223-closing-in?utm_source=finwire&utm_medium=RSS